<DOC>
	<DOCNO>NCT02592707</DOCNO>
	<brief_summary>The purpose clinical phase I/II study investigate safety tolerability 177Lu-OPS201 used treatment patient neuroendocrine tumor ( NETs ) . Secondary objective study assessment biodistribution , dosimetry preliminary efficacy 177Lu-OPS201 .</brief_summary>
	<brief_title>Study Evaluate Safety Preliminary Efficacy 177Lu-OPSC001 NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>1 . Written informed consent . 2 . Patients either gender , age ≥ 18 year . 3 . Women childbearing potential ( surgically sterile less 2 year postmenopausal ) must use medically accept method contraception must agree continue use method duration study 6 month last dose . Acceptable method contraception include abstinence , double contraception : steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method ( intrauterine device , condom etc. ) . 4 . Male patient must use medically accept method contraception must agree continue use method duration study 6 month last activity administration . 5 . Karnofsky performance score ≥ 60 . 6 . Life expectancy least 6 month . 7 . Histologically confirm diagnosis unresectable GEP NET ( Grade I Grade II accord WHO classification ( 2010 , Annex 01 ) , function nonfunctioning ) . unresectable lung NET Grade I Grade II ( low intermediate grade ) ( Klimstra et al 2010 ) malignant , unresectable pheochromocytoma paraganglioma 8 . Documentation progressive disease base RECIST v1.1 prior antitumor therapy within 6 month entry study . Patients receive antitumor therapy disease progression document . The image evaluation available TGR evaluation . 9 . In country sunitinib everolimus market , patient GEP NET lung NET progressive prior antitumor treatment respective indication . Patients suitable everolimus/sunitinib therapy accord tumor board decision ( comparable local practice ) may also enrol study . Patients everolimus/sunitinib therapy washout phase ≥ 4 week first treatment . 10 . Measurable disease base RECIST v1.1 . 11 . Confirmed presence somatostatin receptor technically evaluable tumor lesion document positive Somatostatin Receptor Scan perform within 6 month prior enrolment study . 12 . Calculated GFR ≥ 55 mL/min . 13 . Blood test result follow : Leukocytes : ≥ 4*10^9/L Erythrocytes : ≥ 3.5*12^9/L Platelets : ≥ 100*10^9/L Albumin : &gt; 30 g/L ALT , AST , AP : ≤ 5 time ULN ( upper limit normal ) Bilirubin : ≤ 2 time ULN ( 2x 1.1 mg/dL ) 1 . Known hypersensitivity 177Lu , DOTA , JR11 excipients 177LuOPS201 . 2 . Any previous peptide receptor radionuclide therapy ( PRRT ) . 3 . Diagnosis thymic NET . 4 . Presence active infection screen history serious infection within previous 6 week . 5 . Administration investigational medicinal product within 60 day prior entry . 6 . Prior plan administration therapeutic radiopharmaceutical within 8 halflives radionuclide include time current study . 7 . Any extensive radiotherapy ≤ 3 month enrolment . 8 . Chemotherapy ≤ 3 month enrolment . 9 . Pregnant breastfeed woman : A pregnancy test perform start study female patient childbearing potential ( i.e . surgically sterile 2 year postmenopausal ) . 10 . Any uncontrolled significant medical , psychiatric surgical condition ( active infection , unstable angina pectoris , cardiac arrhythmia , poorly control hypertension , poorly control diabetes mellitus [ HbA1c ≥9 % ] , uncontrolled congestive heart disease , etc . ) laboratory finding , opinion investigator , might jeopardize patient 's safety would limit compliance objective assessment study . Note : patient able tolerate high volume load . 11 . Current history malignancy NET within 5 year enrolment except fully resect nonmelanoma skin cancer cervical cancer situ . Current history malignancy ; patient secondary tumor remission &gt; 5 year include 12 . Any mental condition render patient unable understand nature , scope possible consequence study , and/or evidence uncooperative attitude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>